Millipore Corporation And Novozymes Biopharma Launch Innovative CellPrime Product For Large Scale Industrial Cell Culture
Millipore Corporation and Novozymes Biopharma recently announced the launch of CellPrime™ rAlbumin AF-G, a completely animal-free cell culture supplement designed for large scale industrial bioprocessing applications. This groundbreaking product will be showcased at the Millipore booth (#107) and the Novozymes Biopharma booth (#207) at the Protein Engineering Summit (PEGS), which is being held in Boston, Massachusetts between April 6th and April 10th.
CellPrime™ rAlbumin AF-G was developed in response to increasing demand for cell culture supplements that contain no human or animal ingredients in order to ease regulatory concerns for biopharmaceutical manufacturers. CellPrime™ rAlbumin AF-G offers multiple benefits including the maintenance of osmotic balance and transport, the distribution of fatty acids and amino acids, as well as improving consistency of customers' industrial cell culture processes.
"A critical part of Millipore's long-term strategy is to expand our portfolio of animal-free cell culture supplements we can offer to our customers," said Andrew Bulpin, Vice President of Millipore's Upstream Bioprocessing Business Unit. "CellPrime™ rAlbumin AF-G meets the unique challenges of industrial cell culture by providing a defined, animal-free albumin, which enables customers to take advantage of the benefits of albumin without the challenges associated with animal or human derived supplements."
CellPrime™ rAlbumin AF-G is the third product to be launched in the animal-free CellPrime™ range and further strengthens the existing partnership between Novozymes and Millipore. Building on Millipore Corporation's and Novozymes Biopharma's strong positions in the biopharmaceutical market, this new product will be manufactured by Novozymes Biopharma and sold exclusively through Millipore's sales organisation. The strength and expertise of both alliance partners assures the reliable long-term supply of these regulatory compliant supplements.
The CellPrime™ portfolio provides a completely new offering in cell culture supplements to the biopharmaceutical market. Caspar Foghsgaard, Senior Manager, Novozymes Biopharma comments, "We are delighted to launch CellPrime rAlbumin AF-G to market, and in partnership with Millipore we can offer a secure, consistent supply of this animal-free albumin to all our customers."
Samples of CellPrime™ rAlbumin AF-G are available through Millipore by visiting www.millipore.com/cellprime. For smarter cell culture and the chance to win a Nintendo DS® Lite please visit Novozymes booth #207 and Millipore booth #107 at PEGS, The Westin Copley Place, Boston, Massachusetts, USA. For more information visit http://biopharma.novozymes.com.
About Millipore
Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide. For more information, visit http://www.millipore.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries Novozymes creates tomorrow's industrial biosolutions, improving the customers' business and the use of the planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations increase industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. Read more at www.novozymes.com.
SOURCE: Novozymes Biopharma US Inc.